IP Library Granted Patent US 7,767,654
Granted Patent B2
US 7,767,654 · App. 11/140,504 · Granted Aug 3, 2010

Methods for treating bleeding disorders using sulfated polysaccharides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,767,654
App. No.
11/140,504
Granted
Aug 3, 2010
Kind
B2
Abstract

Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.

Claims (9)

1. A method for treating a subject having a bleeding disorder selected from the group consisting of a chronic or acute bleeding disorder, a congenital coagulation disorder caused by a blood factor deficiency, and an acquired coagulation disorder, wherein the method comprises administering to said subject a composition comprising a procoagulant amount of a fucoidan, wherein the fucoidan is administered at a dosage of about 0.01 mg/kg to about 100 mg/kg daily.

2. The method of claim 1 , wherein the blood factor deficiency is of one or more factors selected from the group consisting of factor V, factor VII, factor VIII, factor IX, factor XI, factor XII, factor XIII, and von Willebrand factor.

3. The method of claim 1 , wherein the method further comprises administering a therapeutically effective amount of Factor VIII to said subject.

4. The method of claim 3 , wherein the fucoidan and the Factor VIII are present in the same composition.

5. The method of claim 3 , wherein the fucoidan and the Factor VIII are present in separate compositions.

6. The method of claim 5 , wherein the Factor VIII is administered prior to administration of the fucoidan.

7. The method of claim 5 , wherein the Factor VIII is administered subsequent to administration of the fucoidan.

8. The method of claim 5 , wherein the Factor VIII is administered concurrently with the fucoidan.

9. The method of claim 2 , wherein the congenital coagulation disorder is a hemophilia.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055188/0953 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036370/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036375/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2009
From: AVIGEN, INC.
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 022635/0881 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2005
From: JOHNSON, KIRK W.
To: AVIGEN, INC.
Reel/Frame 016709/0070 →